EGFR and small cell lung carcinoma: After an initial benefit with the use of EGFR inhibitors, acquired resistance invariably develops; approximately 60% of the patients develop the T790M mutation, and other mechanisms of resistance include EGFR amplification concurrent with T790M, HER2 amplification, MET amplification, SCLC transformation, and others [9].